Home Healthcare Pharmaceuticals Macular Degeneration Treatment Market

Macular Degeneration Treatment Market Size, Share & Trends Analysis Report By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Route of Administration (Intravenous Route, Intravitreal Route), By Sales Channels (Ambulatory Surgical Centers, Hospitals, Other Sales Channels) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Macular Degeneration Treatment Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Dry Age-related Macular Degeneration
    2. Wet Age-related Macular Degeneration
  2. Macular Degeneration Treatment Market, By Stage of Disease 2022-2034 (USD MILLION/ Units)
    1. Early-stage AMD
    2. Intermediate AMD
    3. Late-stage AMD
  3. Macular Degeneration Treatment Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Intravenous Route
    2. Intravitreal Route
  4. Macular Degeneration Treatment Market, By Sales Channels 2022-2034 (USD MILLION/ Units)
    1. Ambulatory Surgical Centers
    2. Hospitals
    3. Other Sales Channels
  5. Regional Macular Degeneration Treatment Market
    1. North America
      1. North America Macular Degeneration Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
      2. North America Macular Degeneration Treatment Market By Stage of Disease 2022-2034 (USD MILLION/ Units)
        1. Early-stage AMD
        2. Intermediate AMD
        3. Late-stage AMD
      3. North America Macular Degeneration Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Intravitreal Route
      4. North America Macular Degeneration Treatment Market By Sales Channels 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgical Centers
        2. Hospitals
        3. Other Sales Channels
      5. U.S.
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      6. Canada
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
    2. Europe
      1. Europe Macular Degeneration Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
      2. Europe Macular Degeneration Treatment Market By Stage of Disease 2022-2034 (USD MILLION/ Units)
        1. Early-stage AMD
        2. Intermediate AMD
        3. Late-stage AMD
      3. Europe Macular Degeneration Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Intravitreal Route
      4. Europe Macular Degeneration Treatment Market By Sales Channels 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgical Centers
        2. Hospitals
        3. Other Sales Channels
      5. U.K.
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      6. Germany
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      7. France
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      8. Spain
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      9. Italy
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      10. Russia
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      11. Nordic
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      12. Benelux
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      13. Rest of Europe
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
    3. APAC
      1. APAC Macular Degeneration Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
      2. APAC Macular Degeneration Treatment Market By Stage of Disease 2022-2034 (USD MILLION/ Units)
        1. Early-stage AMD
        2. Intermediate AMD
        3. Late-stage AMD
      3. APAC Macular Degeneration Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Intravitreal Route
      4. APAC Macular Degeneration Treatment Market By Sales Channels 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgical Centers
        2. Hospitals
        3. Other Sales Channels
      5. China
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      6. Korea
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      7. Japan
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      8. India
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      9. Australia
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      10. Taiwan
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      11. South East Asia
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      12. Rest of Asia-Pacific
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
    4. Middle East and Africa
      1. Middle East and Africa Macular Degeneration Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
      2. Middle East and Africa Macular Degeneration Treatment Market By Stage of Disease 2022-2034 (USD MILLION/ Units)
        1. Early-stage AMD
        2. Intermediate AMD
        3. Late-stage AMD
      3. Middle East and Africa Macular Degeneration Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Intravitreal Route
      4. Middle East and Africa Macular Degeneration Treatment Market By Sales Channels 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgical Centers
        2. Hospitals
        3. Other Sales Channels
      5. UAE
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      6. Turkey
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      7. Saudi Arabia
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      8. South Africa
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      9. Egypt
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      10. Nigeria
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      11. Rest of MEA
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
    5. LATAM
      1. LATAM Macular Degeneration Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
      2. LATAM Macular Degeneration Treatment Market By Stage of Disease 2022-2034 (USD MILLION/ Units)
        1. Early-stage AMD
        2. Intermediate AMD
        3. Late-stage AMD
      3. LATAM Macular Degeneration Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Intravenous Route
        2. Intravitreal Route
      4. LATAM Macular Degeneration Treatment Market By Sales Channels 2022-2034 (USD MILLION/ Units)
        1. Ambulatory Surgical Centers
        2. Hospitals
        3. Other Sales Channels
      5. Brazil
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      6. Mexico
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      7. Argentina
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      8. Chile
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      9. Colombia
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
      10. Rest of LATAM
        1. Dry Age-related Macular Degeneration
        2. Wet Age-related Macular Degeneration
        3. Early-stage AMD
        4. Intermediate AMD
        5. Late-stage AMD
        6. Intravenous Route
        7. Intravitreal Route
        8. Ambulatory Surgical Centers
        9. Hospitals
        10. Other Sales Channels
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.